Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;36(8):e646-e648.
doi: 10.1111/jdv.18110. Epub 2022 Apr 6.

Safety of ustekinumab in adolescent patients with moderate-to-severe plaque psoriasis: real-world evidence from an ongoing European study (NCT03218488)

E Mahé  1 , A Geldhof  2 , M Jazra  3 , P Bergmans  4 , A Azzabi  5 , M M B Seyger  6
Affiliations

Safety of ustekinumab in adolescent patients with moderate-to-severe plaque psoriasis: real-world evidence from an ongoing European study (NCT03218488)

E Mahé et al. J Eur Acad Dermatol Venereol. 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

E. Mahé has undertaken paid activities as consultant, advisor or speaker for AbbVie, Amgen, Celgene, Janssen, Leo Pharma, Lilly and Novartis. A. Geldhof, M. Jazra, P. Bergmans and A. Azzabi are employees of Janssen and may own company stock/stock options. M.M.B. Seyger received grants from/was involved in clinical trials with AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Leo Pharma and Pfizer; and served as a consultant for AbbVie, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer and UCB, with fees paid directly to her institution.

Figures

Figure 1
Figure 1
Percentage of AEs related to ustekinumaba treatment (n = 72) by (a) system organ class and by (b) preferred term. AEs designated as ‘Other’ had ≤3 events related to ustekinumab. aAn AE related to ustekinumab is defined as an AE with a possible, probable or very likely relationship to ustekinumab. AE, adverse event.
See this image and copyright information in PMC

References

    1. Bronckers IMGJ, Paller AS, West DP et al. A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents. JAMA Dermatol 2020; 156: 384–392. - PMC - PubMed
    1. Landells I, Marano C, Hsu M‐C et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate‐to‐severe plaque psoriasis: results of the randomized Phase 3 CADMUS study. J Am Acad Dermatol 2015; 73: 594–603. - PubMed
    1. Bronckers IMGJ, Paller AS, van Geel MJ, van de Kerkhof PCM, Seyger MMB. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Pediatr Drugs 2015; 17: 373–384. - PMC - PubMed
    1. Fortina AB, Bardazzi F, Berti S et al. Treatment of severe psoriasis in children: recommendations of an Italian expert group. Eur J Pediatr 2017; 176: 1339–1354. - PubMed
    1. Phan C, Beauchet A, Burztejn A‐C et al. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. J Eur Acad Dermatol Venereol 2019; 33: 1984–1992. - PubMed

Publication types

Grants and funding